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Abstract. Sickle pain is the hallmark of sickle cell disease (SCD). It could be acute,
persistent/relapsing, chronic, or neuropathic. Although there is a general consensus that pain is a
major manifestation of SCD, there is a controversy as to the types of pain and their
interrelationship between acute, chronic, relapsing, persistent, etc. This report first reviews the
general approach to the management of acute vaso-occlusive crisis (VOC) pain, including
education, counseling, pharmacotherapy, non-pharmacotherapy, and fluid therapy. This is
followed by the presentation of five patients that represent typical issues that are commonly
encountered in the management of patients with SCD. These issues are: individualized treatment
of pain, bilaterality of pain, use of illicit drugs, tolerance to opioids, opioid-induced hyperalgesia,
and withdrawal syndrome. The clinical aspects and management of each of these issues are
described. Moreover, such complications as tolerance and withdrawal may persist after discharge
and may be mistaken as chronic pain rather than resolving, persistent or relapsing pain.
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Introduction. The hallmark of sickle cell disease (SCD)
is the recurrent acute painful vaso-occlusive crises
(VOCs) and the persistent pain (PP) in between crises in
about 50% of adults and 9% of children.1-3 These types
of pain are unique to patients with SCD and punctuate
the quality of their life with uncertainty, suffering, poor
education, poverty, dysfunctional family life, and
dependence on a fragile medical support system. The
frequency, severity, location, and duration of both the
VOCs and PP vary considerably among patients and
longitudinally in the same patient. The reasons for these
fluctuations are not well known.4 Moreover, most
patients present with neither obvious precipitating
factors nor objective signs.5-7 This state of affairs creates
suspicion among some providers about the authenticity
of the VOCs and the resulting accusations of

maladaptive behavior.8
The PP between crises has been labeled as chronic
pain by some providers.1 By doing so, the uniqueness of
sickle cell pain is undermined, and the patients with
SCD are lumped with other chronic pain syndromes in
the general population. This lumping rendered the PP
subject to the rules, regulations, and guidelines for the
treatment of chronic pain.9 Moreover, since patients
with SCD use relatively frequent and large doses of
opioids, they have been assumed to be associated with
the opioid epidemic. Consequently, patients with SCD
and pain became often unfairly undertreated with
opioids.
The purpose of this report is to describe patients with
SCD who presented with different pain characteristics
that were addressed and resolved in a manner based on
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the changing reality of pain among patients over the
dimensions of space and time.10
Overview of Treatment
Education and counseling.
Educating
and
counseling patients with SCD is a continuous process
that starts when first seen and continues through future
follow-ups. I explain the beneficial and harmful effects
of prescribed medications, including opioids.
Prescriptions are given as needed. Vaccines are
administered when required.11 Patients, parents, and
other family members are instructed on what to expect
regarding sickle cell syndromes by making them aware
of the signs and symptoms of VOCs, infection, acute
chest syndrome (ACS), etc. The adoption of good health
habits is reinforced, and the avoidance of situations and
factors that could precipitate a VOC is emphasized.5,11
This process of education and counseling results in a
written consent form and individualized treatment plan
with the patient or parents if long-term opioids are
indicated.12 The agreement lists the patient's rights and
responsibilities, and the treatment plan contains the type,
amount, and route of administration of the opioid in
question, including random drug urine testing.
Pharmacotherapy of Pain. I use nonsteroidal antiinflammatory drugs (NSAIDs), short-acting opioids,
and adjuvants to treat acute pain.13,14 The use of
NSAIDS is limited to patients whose serum creatinine is
≤ 1.0 mg/dL, and they have no proteinuria or
albuminuria. The adjuvants include antihistamines,
antiemetics,
laxatives,
antidepressants,
and
gabapintinoids as needed. I go over the personal side
effects of opioids listed in Table 1. The use of opioids
by patients with SCD is not as problematic as it is in the
general population. A review of data from the Centers
for Disease Control and Prevention (CDC) between
1999 and 2013 showed that less than 1% of deaths
among patients with SCD was due to opioid overdose,
and this low rate of mortality did not change
significantly over the 15-year data.15
Fluid Therapy. I encourage my patients to use water for
oral hydration and avoid soft drinks as often as possible.
Signs and symptoms of dehydration include dry mouth,
tongue, and lips, decreased skin turgor, flat neck veins,
and serum creatinine level higher than steady-state
values. I do not use normal saline for intravenous
hydration but use 5% DW or other crystalloids. I
monitor the status of hydration by determining daily
fluid intake and output, daily weight, and check if edema
develops.16-18 Overhydration, like over blood transfusion,
could be fatal.19-21
Beyond Pharmacotherapy. With the help of our social
workers, we address the psychosocial factors that
pertain to each patient and recommend solutions. We

Table 1. Opioid Risks.
1. Mild/Moderate Side Effects:
• Sedation
• Confusion
• Nausea
• Dizziness
• Constipation
2. Serious Medical Side Effects:
• Gonadal suppression
• Respiratory suppression
• Sleep apnea
• Dental complications
3. Serious Neurological and Behavioral Side Effects:
• Physical dependence
• Withdrawal
• Tolerance
• Hyperalgesia
• Addiction
• Pseudo addiction
• Abuse, misuse, diversion

also recommend nonpharmacologic therapies such as
meditation, yoga, massage, relaxation, tai chi, etc.22,23
Neuropathophysiology of Pain. This was previously
reported10 and summarized in Table 2 and Figure 1.24
Table 2. Pathways of the Transmission of painful Stimuli.
Peripheral nervous system
Peripheral nerves
• Voltage gated sodium channels
• Nav1.7 – Na v1.9
• Dorsal root ganglion
2.
Central nervous system
– Dorsal horn of the spinal cord
• Voltage gated sodium channels
• α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)
– Voltage Gated Calcium Channels
• N-methyl-D-aspartate (NMDA) Receptor
• alpha2-delta (α2-δ) subunit
– Opioid Receptors: µ, ĸ, δ
3.
Central Sensitization
4.
Glial Activation
1.

–

Patient 1: A woman with Hb SC disease and VOC
that went amiss. A 39-year old African American
woman known to have hemoglobin (Hb) SC disease was
admitted to the hospital with the diagnosis of VOC. The
pain involved the left shoulder and the upper/lower back
and was constant, sharp and throbbing in nature with an
intensity score of 10 on a scale from 0 (no pain) to 10
(most severe pain). Past medical history was significant
for VOCs at a rate of 2-3 VOCs per year with no pain
between VOCs, avascular necrosis (AVN) of the left
humeral joint, pneumonia, urinary tract infection, and a
remote history of allergy to morphine. In the emergency
department (ED), she was given meperidine 125 mg
intravenously (IV) every two hours. She did not achieve
adequate pain relief after receiving 3 doses of
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Figure 1. Pathways through which pain stimuli are transmitted from the periphery to the brain. Nav1.7 - NaV1.9 are peripheral voltagegated sodium channels; DRG: Dorsal root ganglion; DH: Dorsal horn of the spinal cord; T: Thalamus; RF: Reticular formation; LS: Limbic
system. Adapted from Semin Hematol 2001; 38(4):307-314. Used with permission.

meperidine and, hence, was admitted to the hospital. The
attending provider decided to start her on patientcontrolled analgesia (PCA) pump using morphine
lockout dose 1 mg, lockout interval 10 minutes, and a
one-hour dose limit of 8 mg morphine. The patient
indicated that she is allergic to morphine and usually
receives meperidine for pain, but she could not give
details about the nature of the allergy to morphine.
About 8 hours after starting the PCA, she experienced
hallucinations, disorientation, fever 103 ͦ F, chest
oppression, and difficulty breathing with pulse
Oximetry of 86%. She was transferred to the intensive
care unit and intubated. The chest x-ray was normal. She
recovered within 24 hours, and management of pain was
resumed with meperidine and was discharged 7 days
after admission.
Comments on patient 1. Management of patients with
sickle cell pain should be individualized. Patients with
SCD are authorities on their disease. They know what
helps them most. Accordingly, providers should listen,
believe, and respect patients unless proven otherwise.
The selection of a specific opioid and its dose should be
based on the patient's previous experience. No opioid or
a specific dose of an opioid applies to all patients all the
time. Opioids are ligands that bind to receptors and slow
the transmission of painful stimuli along the central
nervous system pathways. The binding to and activation
of a specific receptor by an opioid vary considerably
among patients. Opioid receptors are G protein-coupled

with exogenous and endogenous opioids as ligands.25
Recent studies25-27 have revealed a helical structure of
the opioid receptors, which forms pockets in which the
corresponding ligand (opioid) fits snugly. Not all
opioids fit snugly into the same receptor's pocket. This
explains why some patients may have better analgesia
with a certain opioid but not with another opioid.
Patient 2: A man with SCA and urine drug screen
positive for cannabis and phencyclidine. A 22 yearold-African American man with sickle cell anemia
(SCA) whose past medical history was significant for
frequent VOCs that required hospitalizations > 5 times
per year with intermittent pain between VOCs. Pain
during crises was usually constant, sharp, and throbbing
in nature with a score of 8-10/10 and involved the low
back, right shoulder, knees, and legs. Complications of
his disease included ACS, AVN of hips and right
shoulder, priapism, and frequent blood transfusions. In
addition, he had asthma as a child and heparin-induced
thrombocytopenia. He refused to take hydroxyurea.
Social history was positive for tobacco, cannabis, and
alcohol use. Lab data in the steady-state included Hb
that varied between 8 and 10 g/dL, Hb F 11%,
reticulocyte count 10-15%, WBC count 8 – 14 B/L,
normal platelet count, mildly elevated total bilirubin
level and normal hepatic and renal parameters. Pain
management included morphine and ketorolac during
hospitalizations and oxycodone/ acetaminophen
(Percocet) as an outpatient.
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When first seen in our center, agreement, and consent
forms that included random urine drug testing were
discussed and signed by the patient and the provider.
The first random urine drug testing done was positive
for opiates and cannabinoids. Intensive counseling
indicated that he smoked cannabis because Percocet did
not give him adequate pain relief. The issue was
resolved by replacing Percocet with morphine for the
treatment of pain as an outpatient with the patient
affirmation that he will discontinue using cannabis
subject to confirmation by random urine drug testing.
Indeed, random urine drug testing one year later was
negative for cannabis and positive for the opiates
(morphine) he was taking. Unfortunately, the random
urine drug testing done later when he was 24 years old
was positive for opiates and phencyclidine.
Another round of counseling revealed that
phencyclidine gave him much better pain relief than
morphine used to do. Accordingly, pain management
was modified to use methadone up to 60 mg orally/day
instead of morphine and 5% lidocaine patches to apply
over the most painful area for a maximum of 8 hours per
day as needed. Electrocardiogram (EKG) before and
after using methadone showed no prolongation of the
QTC interval. Methadone was chosen because, like
phencyclidine, it inhibits the N-methyl-D-aspartate
(NMDA) channel but less severely. This approach
resulted in the discontinuation of phencyclidine and
repeating urine drug test at the age of 25 years and again
at the age of 26 years when he was last seen was positive
for opiates only and negative for cannabinoids and
phencyclidine.
Comment on patient 2. This patient is a typical example
of opioid tolerance that leads to the use of illicit drugs.
It is defined as reduced potency of the analgesic effect
of an opioid after repeated administration or the need for
higher doses to maintain the same result. It shifts the
dose-response curve to the right (Figure 2A).28 The
binding of an opioid to its receptor generates a series of
reactions that could culminate in tolerance, as shown in
Figure 3.29
Recent studies in mice have shown that tolerance to
morphine seems to be modulated by the gutmicrobiome-central nervous system interactions.30-32
Management of opioid tolerance entails the use of
NMDA inhibitors. Actually, the illicit phencyclidine
used by this patient is a potent inhibitor of the NMDA
(Figure 4) not only at the level of the spinal cord but in
all other tissues and organs and, hence, could be lethal.33
The NMDA channel is a complex structure.34 It is
both a receptor and a calcium-gated channel.35,36
Therapeutic inhibitors of NMDR include ketamine,
clonidine, Lidocaine, dextromethorphan, nitrous oxide,
zinc, and methadone.29,37,38 More recently, rosuvastatin,
B vitamins, and inhibition of platelet-derived growth
factor-β (PDGFR-β) have been shown to attenuate or

Figure 2. Tolerance and hyperalgesia. Tolerance in A shows a
higher dose of an opioid is required to achieve the desired pain relief.
Hyperalgesia in B shows that prolonged administration of opioids
results in a paradoxical increase in severe pain after minor stimuli.
Adapted from Best Pract Res Clin Anaesthesiol 2007; 21:65-83.
Used with permission.

eliminate the development of tolerance to morphine in
rats and mice.39-42 Donica et al. reported that combining
imatinib with a previously ineffective dose of morphine
led to complete pain relief in male Sprague-Dawley
rats.42 In addition, imatinib was effective in treating
sickle cell VOC in patients with chronic myeloid
leukemia and SCA, probably by inhibiting PDGFRβ.43,44
Patient 3: A woman with Hb SC and VOC after Csection that became symmetrically bilateral. A 26year-old pregnant African American woman Hb SC
disease had a Cesarean section (C-section) at week 37
gestation due to signs of fetal distress with abnormal
fetal heart tracing. The surgery was uneventful, and the
fetus survived with a normal APGAR score. Past
medical history was significant for relatively infrequent
VOCs (< 2 per year) and splenic sequestration during
infancy that did not require splenectomy. During
pregnancy, she took oxycodone 5 mg plus
acetaminophen 325 mg (Percocet) prn for pain. The
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Figure 3. The effect of short- and long-term opioid therapy on opioid-receptor signaling. (A) Binding of an opioid to cell membrane µ-receptors
activates the receptor's G protein that dissociates into Gα and Gβγ subunits. These, in turn, inhibit voltage-gated calcium channels and activate
potassium channels resulting in K+ loss causing membrane hyperpolarization and decreased transmission of painful stimuli and opioidanalgesia. However, soon after the opioid binds to its receptor it is subject to phosphorylation by GRK (G-protein-coupled receptor kinase)
culminating in the recruitment and binding of β-arrestin protein to the receptor. This results in desensitization of the receptor thus decreasing
the response to the opioid inducing insufficient analgesia and tolerance. (B) Long term therapy with an opioid associated with sustained βarrestin binding to the receptor often leads to internalization and degradation of the receptor. This, in turn, initiates a series of reactions that
culminate in the activation of the N-methyl-D-aspartate (NMDA) receptor which result in diminishing the analgesic effect, increasing tolerance
and opioid-induced-hyperalgesia. From N Engl J Med 2019; 380:365-378. Used with permission.
Figure 4. The effect of phencyclidine (PCP) on the N-methyl-Daspartate (NMDA) receptor. PCP acts as a noncompetitive
antagonist at NMDA receptor. As long as it is bound it renders the
NMDA receptor nonfunctional. From Breedlove S.M., Watson N.V.
Behavioral Neuroscience, Eighth Edition. Oxford University Press
New York, NY; 2018. Used with permission.

newborn infant had no signs/symptoms of neonatal
abstinence syndrome. She was advised not to breastfeed
her baby. On the 4th post-operative day, she had a sudden
onset of severe pain, swelling, and tenderness in her
right ankle. She achieved partial relief with morphine, 6
mg IV every 2 hours. About 24 hours later, she had the
same severe "mirror image" pain in her left ankle. Some
providers questioned the validity of the symmetrical
pain in the left ankle due to the unlikely possibility of
having vaso-occlusion in such a symmetrical pattern.
Physical exam, however, revealed the presence of
www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e2020064
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similar swelling and tenderness over both ankles. Better
pain relief was achieved by increasing the dose of
morphine to 8 mg IV every 2 hours. She continued to
improve gradually and was discharged with her infant
ten days after admission.
Comment on patient 3. This patient illustrates two
important issues in SCD: postpartum breastfeeding and
the pathophysiology of the incidence of symmetrical
bilateral pain.
Women with SCD who take opioids during
pregnancy must not breastfeed their infants to prevent
newborn withdrawal syndrome that could be fatal.
Codeine used to be considered a safe opioid analgesic
for pain during breastfeeding. This changed after a tragic
case report that pertains to an infant who died at the age
of 13 days from morphine poisoning; the source of
morphine was the codeine that the mother was taking.
Further studies showed that the mother was an ultrarapid metabolizer of codeine, due to duplication of the
CYP2D6 enzyme that metabolized codeine into
morphine.45,46 The recommendation changed, indicating
that women, in general, must not take opioids during the
breastfeeding period.
Symmetrical bilaterality of pain, such as both hips,
both knees, was common in more than 60% of patients
enrolled in the PiSCES study 47 and was also reported by
others.48 The ankles and feet were the most common
locations of bilaterality. The pathophysiology of this
bilaterality is not known. One possibility is that it is
referred pain to a site different than the original site of
pathology.49 Shunting of the blood away from the bone
marrow, the steal syndrome, is another possibility.48
Another explanation of bilaterality is that it is due to
central sensitization at the level of the spinal cord, as
described by Woolf 50 in rats. The convergence of nerve
fibers from two different sites at the same level in the
spinal cord is perceived as pain in both sites (Figure
5).51
Most recently, bilaterality seems to be due to a
phenomenon called "bioelectric injury mirroring".52
This extends our knowledge about the electrophysiology
of regenerative response and identifies a novel
communication process via a long-range spread of
injury signaling (Figure 6).52
Patient 4: A woman with Hb S-β0-thalassemia whose
pain worsened after increasing the dose of morphine.
A 29-year-old African American woman with sickle -β0thalassemia was admitted to the hospital with VOC
involving her low back, chest, and knees. The pain was
typical of her VOCs and was constant and
sharp/throbbing in nature with an intensity score of
10/10. She also complained of fatigue, malaise, nausea,
and vomiting.
Past medical history was significant for frequent
VOCs (≥ 5 per year) that required treatment in the ED

Figure 5. Viscero-somatic convergence of primary afferent fibers
on neurons of lamina I and lamina V of the dorsal horn. IML:
intermediolateral cell column. From Lancet 1999; 353: 2145-2148.
Used with permission.

or in the hospital, cholecystectomy, splenectomy, ACS,
repeated blood transfusions, iron overload, deep vein
thrombosis, migraine headache, urinary tract infection,
and C-section at 34 weeks gestation due to twin
pregnancy with both babies in the breech position.
Pain management in this admission included a
morphine PCA pump with a basal rate of 4 mg/h and 1
mg lockout every 10 minutes with a one-hour dose limit
of 10 mg and ibuprofen. Emesis was controlled with
ondansetron IV. Adjuvants included antihistamines and
laxatives. She required two units of RBC transfusion to
keep her Hb > 8g/dL. She was also given heparin for
deep vein thrombosis prophylaxis. She continued to
complain of severe pain that required increasing the
dose limit of morphine to 16 mg/hour. At the same time,
the distribution and the descriptors of the pain changed;
it became worst in her legs and deep burning in nature.
Examination showed severe allodynia where a
superficial touch of her legs caused severe pain, and she
avoided covering her legs with the blanket to prevent
pain. The diagnosis of morphine-induces hyperalgesia
was made. The dose of morphine was gradually
decreased and replaced with an equianalgesic dose of
hydromorphone, up to 8 mg iv q2hour. Eventually,
adequate relief was achieved with hydromorphone. She
was discharged on the 24th hospital day on
hydromorphone and ibuprofen.
Comment on patient 4. This patient's pain is a typical
example of opioid-induced hyperalgesia (OIH). It is
defined as increased sensitivity to pain stimuli
(hyperalgesia) and pain caused by ordinarily nonpainful
stimuli (referred to as allodynia). Typically,
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Figure 6. Frogs Have a Bioelectric Mirror. (A) Amputation of one limb triggers a rapid electric response that reflects the injury in the
opposite not injured one. From Development 2018; 145: dev164210. (B) Depolarization patterns (brighter green) in the uninjured leg (bottom)
occur within seconds of amputation of the opposing leg (top). From Tufts Now. Amputation injury is communicated to opposing limbs. Tufts
Now; 2019. Used with permission.

hyperalgesia is noted in parts of the body different from
the site of the original pain complaint, and the
descriptors of the pain change with some similarity to
certain aspects of neuropathic pain such as burning
sensation. Unlike tolerance, OIH worsens with higher
doses of opioids (Figure 2B).53-55
The pathophysiology of OIH is not well understood.
A proposed mechanism is the activation of the NMDA
receptor.33,53 This activation results in calcium influx,
which in turn enhances the excitability of neurons,
which facilitates further transmission of painful
stimuli.33
Studies in rats showed that morphine hyperalgesia
appears to be secondary to the activation of specific
receptors within microglia since the ablation of the
microglia prevented OIH.56 Figure 7 illustrates how glia
interact with neurons and the surrounding blood
vessels.57
Management of OIH involves weaning from opioids,
opioid rotation, and the use of NMDA inhibitors such as

methadone, clonidine, Lidocaine, or ketamine as needed.
Weaning and rotation are usually done together, as was
described in this patient.
Patient 5: A man with SCA and recurrent severe
pain between VOCs. A 42-year-old African American
man with SCA presented to the ED with severe diarrhea
and nausea/vomiting of five-days duration. These signs
and symptoms were associated with nasal congestion,
rhinorrhea, cough, and severe crampy abdominal pain
and a VOC with severe pain involving his low back,
arms, and legs that brought him to the ED. Medications
included
Hydroxyurea
1500
mg/day
and
hydromorphone 4 mg by mouth q 2h as needed.
Other complications of his SCA included a history of
cholecystectomy, obstructive sleep apnea treated at
home with oxygen, AVN of the right hip that required
arthroplasty, and pneumonia.
Physical exam included a temperature of 99.6°F, RR
30/min heart rate 130/min, pulse oximetry 99% on 2
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Figure 7. Different types of glia interact with neurons and the surrounding blood vessels. Oligodendrocytes wrap myelin around axons to
speed up neuronal transmission. Astrocytes extend processes that ensheath blood vessels and synapses. Microglia keep the brain under
surveillance for damage or infection. From Nature 2009; 457: 675-677. Used with permission.

liters oxygen. The patient was restless, anxious, and
sweaty. Heart and lung exams were normal. A large
ulcer over the left lateral ankle and a smaller ulcer over
the right medial ankle were both clean and healing
gradually.
Lab data included Hb 7.7 g/dL, reticulocyte count
7.9%, mean corpuscular volume (MCV) 120 fL, serum
creatinine 1.0 mg/dL and normal serum electrolytes and
liver function tests. A diagnosis of VOC precipitated by
viral gastroenteritis was made and treated accordingly.
Cultures of stools, urine, and blood were all negative.
Chest X-ray and EKG were within normal. Treatment
included
hydration,
opioid
analgesia
with
hydromorphone up-to 8mg q 2h IV plus hydroxyzine as

an adjuvant, antiemetics with ondansetron, and antilaxatives with loperamide. He improved gradually, and
after 15 days of hospitalization, he was discharged on
hydromorphone 4 mg by mouth q2h and acetaminophen
325 mg/oxycodone 5 mg three times daily as needed.
During the six months after this hospitalization, he
was readmitted about once every month with similar
signs and symptoms. The diagnosis was changed to
gastroenteritis of unknown etiology. The home
treatment of pain was changed up to 16 mg
hydromorphone po every 2 hours. At this point, he was
referred to our center for advice.
A detailed review of the history and the physical
exam revealed that the patient had adequate pain relief
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with hydromorphone used at home for 3-4 days. After
that, he gradually developed diarrhea, nausea/vomiting,
running nose, abdominal cramps, followed by typical
symptoms of VOC. This sequence of events recurred
before the frequent hospital admissions mentioned
above. This sequence of events was typical of
withdrawal signs and symptoms, and which was treated
with clonidine (0.2 mg three times daily) and methadone
(30 mg daily that was increased gradually to a maximum
of 60 mg/day The patient improved gradually and the
gastrointestinal and respiratory signs and symptoms
resolved. He was advised to continue taking clonidine
and methadone for 3-4 weeks, after which he will be
reevaluated for possible changes.
Comment on patient 5. Withdrawal syndrome is a
conglomerate of physical and behavioral signs and
symptoms after the discontinuation or decreasing the
dose of an opioid or other addictive drug. The severity
of the symptoms depends on the drug in question and its
dosage. These include yawning, sweating, lacrimation,
rhinorrhea, anxiety, irritability, restlessness, insomnia,
dilated pupils, piloerection, chills, tachycardia,
hypertension, nausea/vomiting, cramping abdominal

pains, diarrhea, and muscle aches and pains.
The incidence and management of withdrawal in
SCD have not been well studied. It is often confused
with acute or chronic pain, infection, or other
comorbidities. It is a cause for hospital readmission
within one-two weeks after discharge.58
Treatment of severe opioid withdrawal includes
methadone plus clonidine either orally (0.1- 0.2 mg
every 4-6 hours prn or by using transdermal clonidine
patch 0.1 mg daily. Other drugs that may be used to treat
withdrawal include buprenorphine plus naloxone
orally.59,60 Recently, the FDA approved oral lofexidine
to treat the symptoms of withdrawal.61 Lofexidine is a
structural analog of clonidine. Clinical trials comparing
the two medications showed comparable efficacy,
though the severity of adverse events was less than those
with clonidine. This decreased risk for adverse effects
could potentially make lofexidine a safer option for
detoxification.62-64
Persistent Sickle Cell Pain. The word "chronic" in
SCD is problematic and subject to different explanations.
Thus, SCD itself is a chronic disease that is usually
symptomatic from childhood through adulthood.

Table 3. Emergency Room Data for Patient 1 – 5.
Patient

Crisis Day

Pain Site Location

Pain Score

Hospital Admission

1

10

Yes

10

No

10

No

10

No

10

No

10

No

76

Chest
Right Thigh
Right Knee
Right Leg
Upper Arms
Elbows
Forearms
Wrists
Hands
Fingers
Lower Back
Hip
Left Side
Chest
Thighs
Legs
Upper Back
Lower Back
Neck
Right Shoulder

10

No

1

Chest

9

No

37

Right Foot

8.5

No

76

Abdomen

8.0

No

1

Chest

Not Given

Yes

60

Legs

Not Given

Yes

87

Abdomen

Not Given

Yes

1

Knees

7

No

33

Lower Back
Arms
Forearms
Shoulders

8

No

Not Given

Yes

33
Patient 1
75

114
1
Patient 2

Patient 3

Patient 4

Patient 5

50

54
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Typically, SCD pain is either acute, which is the
hallmark of the disease or chronic. The latter includes
such complications as leg ulcers, AVN of humeral or
femoral heads, and bone infarcts.65-67
These chronic pain syndromes are localized and last
for months or years. Recently chronic pain in SCD has
been defined as ongoing pain that is present in at least
50% of days over 3 or 6 months in a single or multiple
locations.6,68 The problem with this definition is that
during the period of 3- or 6-months, patients with SCD
may have been treated for acute pain in the ED or
hospital, thus confounding this definition. Another
definition of chronic pain that was initially introduced
by surgeons is acute pain that becomes chronic. This
definition applies well to post-operative pain that is
acute after surgery but, in some patients, continues in the
same operative field for months or years.69
Actually, this definition applies to the chronic
complications of SCD. Thus, AVN of the hips may start
acutely but persists for months or years in the same
location. A new definition of chronic pain in SCD is the
pain that persists or occurs between VOCs, the so-called
chronic on acute pain.70 Although this may occur in
disorders other than SCD, it is not typical of SCD
because the sickle pain between VOCs is not the same:
it varies in location, severity, and outcome, as shown in
Table 3. Other patients with chronic pain syndromes
such as fibromyalgia, osteoarthritis, rheumatoid arthritis,
low back pain, migraine, etc. are rarely treated in the ED
and rarely require hospital admissions. Sickle cell

disease and sickle cell pain are unique and should be
considered as such.
Patients discharged from the hospital after treatment
of uncomplicated VOCs may have:
1. No pain.
2. Resolving mild pain as the VOC continues to resolve
gradually.
3. Persistent pain after discharge that requires
continued therapy with oral analgesics, (due to
tolerance, OIH or withdrawal).
4. Relapsing pain that occurs after a period with no pain
(new mild VOC)
I consider the pain that occurs between VOCs is most
likely due to tolerance to opioids, withdrawal syndrome,
OIH, resolving, or acute relapsing pain. These are
specific diagnoses that have specific recommended
treatments rather than treating them as chronic pain.
Accordingly,
it
seems
the
use
of
Buprenorphine/Naloxone is potentially a good
candidate to treat these syndromes as recently reported
by Osunkwo et al.71
Summary. The acute painful VOC is a unique and
hallmark clinical entity of SCD. Recurrent VOCs are not
identical but usually vary considerably among patients
and longitudinally in the same patient. This is unlike
chronic pain that tends to be essentially the same from
time to time. The pain between VOCs could be due to
tolerance, OIH, withdrawal, resolving, or relapsing
VOC.
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